Short-term cilofexor and SC-435 treatment in cholestatic Cyp2c70 knockout mice
Animal study · Male and female Cyp2c70 knockout mice on a C57BL/6J background, treatment from 12 to 14 weeks of age [1]
Dietary cilofexor lowered serum ALT in both sexes, suppressed hepatic Cyp7a1 and induced Bsep. Responses were mixed: cilofexor alone increased CK19-positive ductular cells and collagen-gene expression; lower Sirius Red staining did not establish uniform fibrosis reversal. Adding SC-435 generally improved more injury endpoints. Neither regimen significantly lowered hepatic bile acid hydrophobicity. These endpoints belong to one randomized-by-cage treatment design, not independent studies.
| Endpoint | Reported result | Reference |
|---|---|---|
| Serum ALT relative to chow-fed knockout mice | direction Lower with cilofexor alone in both sexes | [1] |
| Hepatic Cyp7a1 and Bsep mRNA | direction Cyp7a1 decreased; Bsep increased with cilofexor | [1] |
| Ductular reaction, collagen expression and Sirius Red staining | direction Cilofexor alone increased CK19-positive cells and Col1a1/Col1a2 expression; Sirius Red distributions were lower but no uniform monotherapy antifibrotic benefit established | [1] |
| Calculated hydrophobicity of hepatic bile acids | direction No significant reduction versus chow-fed knockout mice with cilofexor alone or combined with SC-435 | [1] |
Conditions shared by the study groups
- Route
- Oral, in chow
- Frequency
- Ad libitum dietary exposure
- Treatment course
- 2 weeks
- Vehicle
- Chow
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| Cilofexor alone 0.015% wt/wt; approximately 30 mg/kg/day | Chow-fed knockout mice; WT chow-fed littermates provide healthy reference | ALT lower in both sexes; hepatic FXR target response; mixed histological and collagen-expression effects. | [1] |
| Cilofexor plus SC-435 Cilofexor 0.015% plus SC-435 0.006% wt/wt (approximately 30 plus 11 mg/kg/day) | Knockout chow, cilofexor alone and SC-435 alone; WT reference | Generally greater reductions in injury markers than monotherapy; hydrophobicity not significantly reduced. Combination benefit cannot be assigned to cilofexor alone. | [1] |
| SC-435 comparator 0.006% wt/wt; approximately 11 mg/kg/day | Chow-fed knockout mice | Comparator reduced several injury endpoints; hepatic Cyp7a1 response differed from cilofexor. | [1] |
- Cilofexor alone
- Model: Male and female Cyp2c70 knockout mice on a C57BL/6J background, treatment from 12 to 14 weeks of age
- Cilofexor plus SC-435
- Model: Male and female Cyp2c70 knockout mice on a C57BL/6J background, treatment from 12 to 14 weeks of age
- SC-435 comparator
- Model: Male and female Cyp2c70 knockout mice on a C57BL/6J background, treatment from 12 to 14 weeks of age
Methods and source locations
Compound reported in the paper: Cilofexor; Compound label in the paper: Cilo
Compound-level mouse research; dietary exposure, not gavage; no salt conversion, potency or lot-validation claim.
Materials/Mouse Study and assay methods; Figures 1–5, 7–8; relevant Results and Discussion
Serum ALT relative to chow-fed knockout mice: Serum chemistry; boxplots show median, IQR, range and individual mice; no curve-derived numerical estimates. — Figure 1B–C; Results, Short-Term Treatment paragraph 2
Hepatic Cyp7a1 and Bsep mRNA: RT-qPCR normalized to cyclophilin D and expressed relative to WT; n = 7–8 mice/group; median, IQR and range. — Figures 4–5; Results, Differentially Regulates hepatic genes
Ductular reaction, collagen expression and Sirius Red staining: Whole-section QuPath quantification: histology n = 4–9 mice/group; gene expression n = 7–8; medians, IQR and range. No exact values inferred from plots. — Figures 2B–C and 3B–C; Results, Short-Term Treatment histology paragraph; Discussion, Short-Term Administration of Cilofexor
Calculated hydrophobicity of hepatic bile acids: Hepatic bile acid analysis; n = 7–8 mice/group; median, IQR and range. — Figures 7B and 8B; Results, Treatment-Induced Reduction in Liver Bile Acid Accumulation
Cilofexor alone · Materials/Mouse Study; Figures 1–5
Cilofexor plus SC-435 · Materials/Mouse Study; Figures 1–3, 7–8
SC-435 comparator · Materials/Mouse Study; Figures 1–5